BR112020002892A2 - forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona, processo para preparar a forma sólida, composição farmacêutica, processo para preparar uma composição farmacêutica, método para tratar câncer em um paciente e método para tratar lesão cerebral traumática em um paciente - Google Patents

forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona, processo para preparar a forma sólida, composição farmacêutica, processo para preparar uma composição farmacêutica, método para tratar câncer em um paciente e método para tratar lesão cerebral traumática em um paciente Download PDF

Info

Publication number
BR112020002892A2
BR112020002892A2 BR112020002892-4A BR112020002892A BR112020002892A2 BR 112020002892 A2 BR112020002892 A2 BR 112020002892A2 BR 112020002892 A BR112020002892 A BR 112020002892A BR 112020002892 A2 BR112020002892 A2 BR 112020002892A2
Authority
BR
Brazil
Prior art keywords
ing
solid form
solvate
fact
methyl
Prior art date
Application number
BR112020002892-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Yamin Zhang
Original Assignee
Actuate Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63405430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020002892(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actuate Therapeutics Inc. filed Critical Actuate Therapeutics Inc.
Publication of BR112020002892A2 publication Critical patent/BR112020002892A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
BR112020002892-4A 2017-08-11 2018-08-10 forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona, processo para preparar a forma sólida, composição farmacêutica, processo para preparar uma composição farmacêutica, método para tratar câncer em um paciente e método para tratar lesão cerebral traumática em um paciente BR112020002892A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
US62/544,277 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (1)

Publication Number Publication Date
BR112020002892A2 true BR112020002892A2 (pt) 2020-08-04

Family

ID=63405430

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020002892-4A BR112020002892A2 (pt) 2017-08-11 2018-08-10 forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona, processo para preparar a forma sólida, composição farmacêutica, processo para preparar uma composição farmacêutica, método para tratar câncer em um paciente e método para tratar lesão cerebral traumática em um paciente

Country Status (16)

Country Link
US (3) US11136334B2 (cg-RX-API-DMAC7.html)
EP (1) EP3665176B1 (cg-RX-API-DMAC7.html)
JP (3) JP7424639B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250070131A (cg-RX-API-DMAC7.html)
CN (2) CN117362305A (cg-RX-API-DMAC7.html)
AU (3) AU2018313259B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020002892A2 (cg-RX-API-DMAC7.html)
CA (1) CA3072240A1 (cg-RX-API-DMAC7.html)
DK (1) DK3665176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974328T3 (cg-RX-API-DMAC7.html)
FI (1) FI3665176T3 (cg-RX-API-DMAC7.html)
IL (2) IL272556B2 (cg-RX-API-DMAC7.html)
MX (3) MX2020001547A (cg-RX-API-DMAC7.html)
PL (1) PL3665176T3 (cg-RX-API-DMAC7.html)
PT (1) PT3665176T (cg-RX-API-DMAC7.html)
WO (1) WO2019032958A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407759B2 (en) * 2017-10-16 2022-08-09 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
KR20210038429A (ko) * 2018-05-17 2021-04-07 액투에이트 테라퓨틱스 인크. 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료
CA3251821A1 (en) * 2022-06-27 2024-01-04 Actuate Therapeutics, Inc. ORAL DOSAGE FORMS OF ELRAGLUSIB

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP2013515737A (ja) 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにその調製方法および使用方法

Also Published As

Publication number Publication date
DK3665176T3 (da) 2024-03-25
WO2019032958A1 (en) 2019-02-14
US11136334B2 (en) 2021-10-05
US20200223861A1 (en) 2020-07-16
KR20250070131A (ko) 2025-05-20
PT3665176T (pt) 2024-03-13
MX2020001547A (es) 2020-08-03
IL272556A (en) 2020-03-31
US20220009939A1 (en) 2022-01-13
MX2024003249A (es) 2024-04-04
CN111247153A (zh) 2020-06-05
JP2026012715A (ja) 2026-01-27
CA3072240A1 (en) 2019-02-14
IL313800A (en) 2024-08-01
US20250115616A1 (en) 2025-04-10
EP3665176A1 (en) 2020-06-17
MX2023005875A (es) 2023-06-05
AU2023201059A1 (en) 2023-03-23
KR20240063198A (ko) 2024-05-09
ES2974328T3 (es) 2024-06-26
EP3665176B1 (en) 2024-01-24
CN111247153B (zh) 2024-04-02
IL272556B2 (en) 2025-01-01
JP2020530497A (ja) 2020-10-22
AU2025202936A1 (en) 2025-05-15
CN117362305A (zh) 2024-01-09
JP2023156372A (ja) 2023-10-24
JP7424639B2 (ja) 2024-01-30
JP7778750B2 (ja) 2025-12-02
AU2018313259B2 (en) 2022-11-24
AU2018313259A1 (en) 2020-02-27
AU2023201059B2 (en) 2025-04-03
PL3665176T3 (pl) 2024-06-17
US12145943B2 (en) 2024-11-19
KR20200040799A (ko) 2020-04-20
FI3665176T3 (fi) 2024-03-20
KR102700883B1 (ko) 2024-09-02
IL272556B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
US20250115616A1 (en) Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
US20250115615A1 (en) Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
BR122025019554A2 (pt) Forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5- f]indol-7-il)pirrol-2,5-diona, seus usos, composição farmacêutica e processo para preparar a mesma
BR112020007538B1 (pt) Forma sólida, processo para preparar a forma sólida, composição farmacêutica, processo para preparar a composição farmacêutica e uso da forma sólida

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25G Requested change of headquarter approved

Owner name: ACTUATE THERAPEUTICS INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025019554-5 PROTOCOLO 870250082551 EM 12/09/2025 17:57.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]